Form 4 for MLYS Mineralys Therapeutics, Inc.
Accepted 2025-03-17 00:00:00 ET · period of report 2025-03-13 · accession 0001415889-25-008274 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2025-03-17 | 2025-03-13 | MLYS | AKKARAJU SRINIVAS | Dir | P - Purchase | $13.50 | +600.0K | 5.67M | +12% | +$8.10M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-13 | P | A | 600,000 | $13.50 | 5,674,916 | I By Samsara BioCapital, L.P. | — | — | (F1) Securities are directly held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. |